Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism. Possible mechanisms of pulmonary pharmacotoxicity

J. A.D. Cooper, W. W. Merrill, Herbert Reynolds

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Cyclophosphamide, an immunosuppressive alkylating agent, has been reported to cause acute and pulmonary injury in both humans and animals. Cyclophosphamide is also a common component of multi-drug regimens that show high pulmonary toxic potential. Although mechanisms of pulmonary damage caused by cyclophosphamide or other cytotoxic agents are unknown, possibilities include direct toxicity to pulmonary tissue or indirect toxicity through activation of pulmonary inflammatory cells. We report here a model system for the study of acute effects of cyclophosphamide on pulmonary immune cells in rats. Our findings show that 16 h after 1 intraperitoneal dose of cyclophosphamide there is: (1) a dose dependent release of locally produced low molecular weight chemotactic factors for blood monocytes into bronchoalveolar lavage (BAL) fluid, (2) a pulmonary influx of immature myeloperoxidase positive macrophages in low dose cyclophosphamide treated animals, (3) an enhancement of oxidant generation by pulmonary macrophages from low dose treated animals that correlates with the presence of myeloperoxidase positive macrophages, (4) the presence of factors in BAL fluid of treated rats that modulate oxidant release by normal rat pulmonary macrophages, (5) a dose dependent reduction in the percentage of BAL lymphocytes, and (6) evidence for pulmonary injury as manifested by elevated BAL fluid albumin concentrations in low dose cyclophosphamide treated animals. These findings suggest that cyclophosphamide may induce pulmonary injury through activation of pulmonary immunocompetent cells and subsequent attraction of systemic inflammatory cells.

Original languageEnglish (US)
Pages (from-to)108-114
Number of pages7
JournalAmerican Review of Respiratory Disease
Volume134
Issue number1
StatePublished - Jan 1 1986

Fingerprint

Cyclophosphamide
Macrophages
Lung
Population
Bronchoalveolar Lavage Fluid
Alveolar Macrophages
Lung Injury
Oxidants
Peroxidase
Acute Lung Injury
Poisons
Alkylating Agents
Chemotactic Factors
Cytotoxins
Bronchoalveolar Lavage
Immunosuppressive Agents
Monocytes
Albumins
Molecular Weight
Lymphocytes

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

@article{156b406eace444209eeb1d149887d3ca,
title = "Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism. Possible mechanisms of pulmonary pharmacotoxicity",
abstract = "Cyclophosphamide, an immunosuppressive alkylating agent, has been reported to cause acute and pulmonary injury in both humans and animals. Cyclophosphamide is also a common component of multi-drug regimens that show high pulmonary toxic potential. Although mechanisms of pulmonary damage caused by cyclophosphamide or other cytotoxic agents are unknown, possibilities include direct toxicity to pulmonary tissue or indirect toxicity through activation of pulmonary inflammatory cells. We report here a model system for the study of acute effects of cyclophosphamide on pulmonary immune cells in rats. Our findings show that 16 h after 1 intraperitoneal dose of cyclophosphamide there is: (1) a dose dependent release of locally produced low molecular weight chemotactic factors for blood monocytes into bronchoalveolar lavage (BAL) fluid, (2) a pulmonary influx of immature myeloperoxidase positive macrophages in low dose cyclophosphamide treated animals, (3) an enhancement of oxidant generation by pulmonary macrophages from low dose treated animals that correlates with the presence of myeloperoxidase positive macrophages, (4) the presence of factors in BAL fluid of treated rats that modulate oxidant release by normal rat pulmonary macrophages, (5) a dose dependent reduction in the percentage of BAL lymphocytes, and (6) evidence for pulmonary injury as manifested by elevated BAL fluid albumin concentrations in low dose cyclophosphamide treated animals. These findings suggest that cyclophosphamide may induce pulmonary injury through activation of pulmonary immunocompetent cells and subsequent attraction of systemic inflammatory cells.",
author = "Cooper, {J. A.D.} and Merrill, {W. W.} and Herbert Reynolds",
year = "1986",
month = "1",
day = "1",
language = "English (US)",
volume = "134",
pages = "108--114",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism. Possible mechanisms of pulmonary pharmacotoxicity. / Cooper, J. A.D.; Merrill, W. W.; Reynolds, Herbert.

In: American Review of Respiratory Disease, Vol. 134, No. 1, 01.01.1986, p. 108-114.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism. Possible mechanisms of pulmonary pharmacotoxicity

AU - Cooper, J. A.D.

AU - Merrill, W. W.

AU - Reynolds, Herbert

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Cyclophosphamide, an immunosuppressive alkylating agent, has been reported to cause acute and pulmonary injury in both humans and animals. Cyclophosphamide is also a common component of multi-drug regimens that show high pulmonary toxic potential. Although mechanisms of pulmonary damage caused by cyclophosphamide or other cytotoxic agents are unknown, possibilities include direct toxicity to pulmonary tissue or indirect toxicity through activation of pulmonary inflammatory cells. We report here a model system for the study of acute effects of cyclophosphamide on pulmonary immune cells in rats. Our findings show that 16 h after 1 intraperitoneal dose of cyclophosphamide there is: (1) a dose dependent release of locally produced low molecular weight chemotactic factors for blood monocytes into bronchoalveolar lavage (BAL) fluid, (2) a pulmonary influx of immature myeloperoxidase positive macrophages in low dose cyclophosphamide treated animals, (3) an enhancement of oxidant generation by pulmonary macrophages from low dose treated animals that correlates with the presence of myeloperoxidase positive macrophages, (4) the presence of factors in BAL fluid of treated rats that modulate oxidant release by normal rat pulmonary macrophages, (5) a dose dependent reduction in the percentage of BAL lymphocytes, and (6) evidence for pulmonary injury as manifested by elevated BAL fluid albumin concentrations in low dose cyclophosphamide treated animals. These findings suggest that cyclophosphamide may induce pulmonary injury through activation of pulmonary immunocompetent cells and subsequent attraction of systemic inflammatory cells.

AB - Cyclophosphamide, an immunosuppressive alkylating agent, has been reported to cause acute and pulmonary injury in both humans and animals. Cyclophosphamide is also a common component of multi-drug regimens that show high pulmonary toxic potential. Although mechanisms of pulmonary damage caused by cyclophosphamide or other cytotoxic agents are unknown, possibilities include direct toxicity to pulmonary tissue or indirect toxicity through activation of pulmonary inflammatory cells. We report here a model system for the study of acute effects of cyclophosphamide on pulmonary immune cells in rats. Our findings show that 16 h after 1 intraperitoneal dose of cyclophosphamide there is: (1) a dose dependent release of locally produced low molecular weight chemotactic factors for blood monocytes into bronchoalveolar lavage (BAL) fluid, (2) a pulmonary influx of immature myeloperoxidase positive macrophages in low dose cyclophosphamide treated animals, (3) an enhancement of oxidant generation by pulmonary macrophages from low dose treated animals that correlates with the presence of myeloperoxidase positive macrophages, (4) the presence of factors in BAL fluid of treated rats that modulate oxidant release by normal rat pulmonary macrophages, (5) a dose dependent reduction in the percentage of BAL lymphocytes, and (6) evidence for pulmonary injury as manifested by elevated BAL fluid albumin concentrations in low dose cyclophosphamide treated animals. These findings suggest that cyclophosphamide may induce pulmonary injury through activation of pulmonary immunocompetent cells and subsequent attraction of systemic inflammatory cells.

UR - http://www.scopus.com/inward/record.url?scp=0022453121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022453121&partnerID=8YFLogxK

M3 - Article

C2 - 3014931

AN - SCOPUS:0022453121

VL - 134

SP - 108

EP - 114

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -